Evidence map›Paper›PMID 42430009›Full record

ArticleBreast cancer research and treatment2026

Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk.

Jacob G Comeaux, Natalia Gutierrez, Charité N Ricker, Qi Nie, Averi Nguyen, Ivan Garcia, Emmeline Y Chang, Rebecca M Waggoner, Susan Groshen, Caryn Lerman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jacob G ComeauxKeck School of Medicine, University of Southern California, Los Angeles, USA. Jacob.Comeaux@med.usc.edu.ORCID http://orcid.org/0000-0002-0944-5079
Natalia GutierrezKeck School of Medicine, University of Southern California, Los Angeles, USA.
Charité N RickerKeck School of Medicine, University of Southern California, Los Angeles, USA.ORCID http://orcid.org/0000-0002-0620-9345
Qi NieUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA.ORCID http://orcid.org/0009-0005-1165-7782
Averi NguyenKeck School of Medicine, University of Southern California, Los Angeles, USA.
Ivan GarciaKeck School of Medicine, University of Southern California, Los Angeles, USA.
Emmeline Y ChangKeck School of Medicine, University of Southern California, Los Angeles, USA.
Rebecca M WaggonerKeck School of Medicine, University of Southern California, Los Angeles, USA.
Susan GroshenKeck School of Medicine, University of Southern California, Los Angeles, USA.
Caryn LermanKeck School of Medicine, University of Southern California, Los Angeles, USA.
Darcy SpicerLos Angeles General Medical Center, Los Angeles, USA.
Julie O CulverKeck School of Medicine, University of Southern California, Los Angeles, USA.ORCID http://orcid.org/0000-0001-8658-3507

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

purposeTo identify factors associated with adherence to breast cancer (BC) screening among women with a pathogenic or likely pathogenic (P/LP) variant in a moderate-risk gene, ATM, BARD1, CHEK2, RAD51C, and RAD51D or with empiric lifetime risk ≥ 20%.

methodsWe reviewed medical records of women without breast cancer who underwent genetic counseling and testing and were advised to undergo annual breast MRI and mammography. Adherence to screening for up to three years was compared between women with a P/LP variant in a moderate-risk gene and women with an elevated empiric risk of 20-40% by the Tyrer-Cuzick model.

resultsThe study population included 44 women with P/LP variants (P/LP group) and 117 with lifetime BC estimates of 20-40% (Empiric group). Within one year, the P/LP group had significantly higher rates of screening than the Empiric group with 58% vs. 37% obtaining breast MRI and 88% vs. 55% obtaining mammograms. Time-to-event analysis demonstrated the P/LP group initiated screening significantly sooner than the Empiric group. After adjusting for having family history of BC or personal history of non-BC, the P/LP group was 3.18 and 7.04 times more likely to obtain breast MRI and mammograms, respectively. Adherence declined in both groups in the second and third year of follow-up.

conclusionWomen with P/LP variants were more adherent to BC screening than those with empiric risk, underscoring the role that genetic test results may play in screening behavior. Future efforts should focus on understanding the barriers to screening and improving long-term adherence.

Indexed as

Breast NeoplasmsEarly Detection of CancerPatient ComplianceAdultAgedFemaleGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingHumansMagnetic Resonance ImagingMammographyMiddle AgedRisk FactorsBreast cancerBreast MRIGenetic testingGermline pathogenic variantMammogramScreening adherence

Identifiers

PMID42430009
PMCPMC13354641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.